Pfizer starts 4 Phase 3 clinical studies for investigational vaccines
Category: #health  By Saipriya Iyer  Date: 2020-06-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

Pfizer starts 4 Phase 3 clinical studies for investigational vaccines

Pfizer Inc. has recently announced the commencement of 4 Phase 3 clinical trials, which are within the pipeline of the company’s investigational vaccines.

Out of these four trials, two studies namely NCT04382326 & NCT04379713 for the vaccine candidate, 20vPnC (20-valent pneumococcal polysaccharide conjugate) are being conducted. These trials are performed among infants of 2 years and above by evaluating a 4-dose series of the vaccine. Both the studies will include a Prevnar 13® control group; while NCT04382326 will determine the immunologic noninferiority of infants between Prevnar 13® and 20vPnC.

Nearly 3,500 infants are likely to be enrolled in these two trials. The infants will either be vaccinated with Prevnar 13® or 20vPnC at ages of 2, 4, 6 or 12-15 months, including other routine vaccines as per the recommended schedule of the Centers for Disease Control & Prevention (CDC).

Another vaccine study namely NCT04424316 will examine the safety and efficacy of the RSV (respiratory syncytial virus) vaccine candidate, RSVpreF. It is a global, placebo-controlled, double-blind study that will be conducted among 6,900 pregnant women of 18 to 49 years and their infants.

The 4th trial namely NCT04440163 will evaluate the immunogenicity, tolerability, and safety of the vaccine candidate, MenABCWY, as compared to the licensed meningococcal vaccines among the young adults and adolescents. This Phase 3 trial of MenABCWY will enroll around 2,413 study participants between 10 to 25 years from Europe and the United States. The initiation of this Phase 3 study is based on the positive results from NCT03135834, a proof-of-concept study that was conducted in 543 young adults and adolescents.

According to Kathrin U. Jansen, Pfizer’s Senior VP and Vaccine Research & Development Head, the initiation of these four Phase 3 trials of the investigational vaccine candidates can be attributed to the efforts of the company’s team of experts. The approval of these 3 vaccines will serve as the potential treatments against various serious and deadly infectious diseases that adversely impact people from different age groups across the globe.

Source credit:

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-start-four-phase-3-clinical-trials



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Target and Kohl’s to sell beauty products as department stores reel
Target and Kohl’s to sell beauty products as department stores reel
By Saipriya Iyer

Some retailers are speculating that eye shadow palettes, facial scrubs, and lip glosses will likely be the upcoming popular thing that would bring significant customer attention, especially the younger generation, to t...

U.S. FDA approves adjunctive therapy & intravenous use of VIMPAT®
U.S. FDA approves adjunctive therapy & intravenous use of VIMPAT®
By Saipriya Iyer

UCB, a biopharmaceutical company, has recently gained the approval of the U.S. FDA (Food & Drug Administration) for its prescription medicine, VIMPAT®.

VIMPAT

ECA alleges Amazon misused non-public data of retailers to its benefit
ECA alleges Amazon misused non-public data of retailers to its benefit
By Saipriya Iyer

The ECA (European Competition Authorities), in preliminary findings, has reportedly alleged that American e-commerce giant Amazon “systematically relied on non-public business information of independent sellers&r...